Rituximab, Mycophenolate Mofetil Compared for Pemphigus Vulgaris
More patients receiving rituximab versus mycophenolate mofetil had sustained complete remission at week 52, fewer had disease flares
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.